Recombinant Human Neuregulin-2/NRG2 His-tag Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 11355-NR

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
11355-NR-100
11355-NR-050
11355-NR-01M
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

CHO

Accession #

O14511.1

Conjugate

Unconjugated

Applications

Bioactivity

View all Neuregulin-2/NRG2 Proteins and Enzymes »

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived human Neuregulin-2/NRG2 protein
Cys112-Lys404, with a C-terminal 6-His tag

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Cys112

Predicted Molecular Mass

34 kDa

SDS-PAGE

41-51 kDa, under reducing conditions.

Activity

Measured in a serum-free cell proliferation assay using MCF-7 human breast cancer cells. Karey, K.P. et al. (1988) Cancer Research 48:4083.
The ED50 for this effect is 0.100-1.00 μg/mL.

Scientific Data Images for Recombinant Human Neuregulin-2/NRG2 His-tag Protein, CF

Recombinant Human Neuregulin‑2/NRG2 His-tag Protein Bioactivity.

Recombinant Human Neuregulin‑2/NRG2 His-tag Protein (Catalog # 11355-NR) induces MCF‑7 human breast cancer cell proliferation. The ED50 for this effect is 0.100-1.00 μg/mL

Recombinant Human Neuregulin‑2/NRG2 His-tag Protein SDS-PAGE.

2 μg/lane of Recombinant Human Neuregulin‑2/NRG2 His-tag Protein (Catalog # 11355-NR) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 41-51 kDa.

Formulation, Preparation and Storage

11355-NR
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Neuregulin-2/NRG2

Neuregulins (NRGs) are a family of six related physiological ligands all containing a receptor-binding epidermal growth factor (EGF)-like domain that mediate their binding to cellular receptors. The EGF-like domain is responsible for binding to the HER RTK family members (EGFR, HER2, HER3, and HER4). Human NRG2, also known as NTAK (neural-and thymus-derived activator for ErbB kinases), is a ~92 kDa, 850 aa protein composed of a 111 aa signal sequence, 294 aa extracellular domain, 21 aa transmembrane domain, and a 424 aa cytoplasmic domain. Human NRG2 shares 95% homology with mouse and rat NRG. NRG-2 encodes six to eight isoforms that contain Ig-like domains near their N-termini. The NRG family are involved in the development of the nervous and cardiovascular systems through the ErbB signaling pathway (1). They also regulate multiple intercellular signal transduction and a wide range of biological processes, such as differentiation, migration, and myelination (2). The primary receptor for NRG-2 is HER4, but binds directly to both ErbB3 and ErbB4, and transactivates ErbB1 and ErbB2 via heterodimerization with ErbB3 or ErbB4 (3, 4). Interaction between NRGs and their receptors plays an important role in the pathogenesis and treatment of neurodegenerative diseases (5). NRGs can be used as targets for therapeutic or clinical trials for their multiple roles in many neurological disorders, such as ALS, brain trauma, spinal cord injury, peripheral neuropathy, and schizophrenia (2). NRG-2 promotes neuronal survival when bound to ErbB3 on neurons (6). NRG-2 can indirectly transactivate HER2 and trigger downstream signaling pathways linked to carcinogenesis, tumor progression, and resistance to cancer therapies (7). NRG-2 binds to HER3 and HER4 to mediate downstream signaling linked to breast cancer initiation and progression (8, 9).

References

  1. Nagasaka, M. and S-H.I. Ou (2022) Trends Cancer 8:242.
  2. Ou, G-Y., et al. (2021) Front. Aging Neurosci. 13:662474.
  3. Carraway, K.L. et al. (1997) Nature 387:512.
  4. Higashiyama, S. et al. (1997) J. Biochem. 122:675.
  5. Bublil, E. M., and Y. Yarden (2007) Curr. Opin. Cell Biol. 19:124.
  6. Nakano N., et al. (2016) Neurosci. Lett. 622:88.
  7. Meyer, D., et al. (1997) Development 124:3575.
  8. Yang, L. et al. (2022) Am. J. Cancer Res. 12:2173.
  9. Centa, A. et al. (2018) Mol. Oncol. 12:1061.

Alternate Names

Don-1, Neuregulin2, NRG2, NTAK

Entrez Gene IDs

9542 (Human); 100042150 (Mouse); 432361 (Rat)

Gene Symbol

NRG2

UniProt

O14511.1

Additional Neuregulin-2/NRG2 Products

Product Documents for Recombinant Human Neuregulin-2/NRG2 His-tag Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human Neuregulin-2/NRG2 His-tag Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.